Related Experiment Videos
Electroencephalogram and treatment of hospitalized aggressive children with haloperidol or lithium
Insights
Electroencephalograms (EEGs) in children with Conduct Disorder showed abnormalities when treated with haloperidol or lithium. Visual EEG evaluation proved valuable in distinguishing treatment groups, despite no clear link to behavioral changes.
Area of Science:
- Child Psychiatry
- Neuroscience
- Pharmacology
Background:
- Conduct Disorder (CD) is a behavioral disorder characterized by aggression and impulsivity.
- Pharmacological interventions, including haloperidol and lithium, are used to manage severe CD symptoms.
- Electroencephalograms (EEGs) can provide insights into brain activity in psychiatric conditions.
Purpose of the Study:
- To investigate the impact of haloperidol and lithium on EEG patterns in children with aggressive CD.
- To determine if EEG changes correlate with medication efficacy or side effects.
- To assess the utility of visual EEG interpretation in differentiating treatment groups.
Main Methods:
- Analysis of EEGs from 48 children (ages 5.2-12.9) diagnosed with undersocialized, aggressive CD.
- Comparison of EEGs under baseline placebo, and optimal dosages of haloperidol, lithium, or placebo.
- Correlation of EEG findings with behavioral ratings and adverse effect assessments.
Main Results:
- 58.3% of children exhibited abnormal EEGs at baseline placebo.
- Haloperidol and lithium treatment were associated with a higher likelihood of worsening EEGs and new paroxysmal or focal abnormalities compared to placebo.
- EEG patterns allowed for the differentiation of children receiving haloperidol, lithium, or placebo.
Conclusions:
- Visual EEG evaluation is a valuable tool in assessing treatment response in children with aggressive CD.
- Haloperidol and lithium can induce significant EEG changes in this population.
- No definitive associations were found between baseline EEGs and behavioral outcomes or side effects.
Abstract:
Electroencephalograms (EEGs) of 48 children ages 5.2 to 12.9 years were examined on baseline placebo and on optimal dosages of haloperidol, lithium, or placebo. These children represent a subgroup of 61 hospitalized aggressive and explosive patients diagnosed as Conduct Disorder, undersocialized, aggressive who completed a double-blind study comparing the efficacy of haloperidol, lithium, and placebo. EEGs were correlated across treatment groups with behavioral ratings, ratings of untoward effects, and optimal dosages of medication. During the baseline placebo period 58.3% of the children had abnormal EEGs. Children receiving haloperidol or lithium had a significant probability that their EEGs on optimal dose would worsen, and would be more likely to show paroxysmal or focal abnormalities than those children treated with placebo. It was possible to identify children treated with haloperidol, lithium, or placebo on the basis of EEG alone. Thus, despite limitations, visual evaluation of EEGs is of value. No statements can be made with confidence regarding associations between baseline EEGs and behavioral changes, side effects, or optimal dosages of haloperidol or lithium.